Table 1.
Baseline characteristics of the study population n (%)
| Characteristic | Value1 | n3 |
| Age, yr | 46.9 ± 15.82 | 498 |
| Male | 341 (68.5) | 498 |
| Female | 157 (31.5) | 498 |
| Molecular findings | ||
| B19V-genotype 1 | 286 (57.4) | 498 |
| B19V-genotype 2 | 183 (36.7) | 498 |
| Endomyocardial biopsy results4 | ||
| Acute myocarditis | 25 (5.0) (3.2 × 105 GE/μg)5 | 498 |
| Inflammatory cardiomyopathy | 297 (59.6) (709 GE/μg)5 | 498 |
| Dilated cardiomyopathy | 176 (35.3) (392 GE/μg)5 | 498 |
| Uninflamed control hearts | ||
| B19V-detection | 7 (7.7) (84 GE/μg)5 | 91 |
| Age (at death), yr | 48.1 ± 20.82 | 91 |
| Male | 49 (53.9) | 91 |
| Female | 42 (46.1) | 91 |
1
Values are number, absolute and relative frequency of patients;
2
Values are expressed as mean and ± SD; 3Total number of patients;
4
Histopathology according to the Dallas criteria[41] supplemented by immunohistochemistry for detection of CD3-positive T-lymphocytes, CD68-positive macrophages and natural killer cells, and HLA class II expression in professional antigen-presenting immune cells as described[18];
5
Values are expressed as mean of B19V-genome equivalents per microgram isolated nucleic acids[4].